Alnylam Pharmaceuticals
30-Second Executive Brief
Executive Assessment
Alnylam Pharmaceuticals functions as an established institution within Healthcare & Life Sciences, backed by 47% sourcing coverage, with accelerating strategic relevance.
- Maintains 3 mapped relationships across the graph
- 47% sourcing coverage across sourced relationships
- Tracked as established institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 47%
- Ecosystem Influence
- High
- Strategic Momentum
- Accelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 4
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
US biotechnology company pioneering RNA interference (RNAi) therapeutics; reported Q2 2026 global net product revenues of $1.172 billion (up 74% year-over-year), driven by TTR amyloidosis franchise revenue of $1.03 billion (up 89%) led by AMVUTTRA, and reiterated full-year 2026 net product revenue guidance of $4.9-5.3 billion.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
1 source
- Business Wire — Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progresscompany
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Alnylam Pharmaceuticals — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Alnylam Pharmaceuticals's Timeline
A sourced, dated history of Alnylam Pharmaceuticals's key moments — founding to present.
Jul 2026 · Q2 2026 net product revenue rises 74% to $1.17 billion on AMVUTTRA growth
Alnylam Pharmaceuticals reported Q2 2026 global net product revenues of $1.172 billion, up 74% year-over-year, driven by total TTR franchise revenues of $1.03 billion, up 89%, led by AMVUTTRA; the company reiterated full-year 2026 net product revenue guidance of $4.9-5.3 billion while revising TTR-specific guidance to $4.2-4.5 billion.